Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 13/20 | 0.36 |
| ▸ | AXL | P30530 | 8/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205198 | 0.90 | POLB (0.37) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL24205067 | 0.78 | TSHR (0.46) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL26034473 | 0.74 | TSHR (0.44) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL24205371 | 0.73 | TSHR (0.45) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL26034598 | 0.73 | POLB (0.38) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL24205077 | 0.72 | POLB (0.44) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL26034607 | 0.72 | TK2 (0.53) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL26034665 | 0.72 | TK2 (0.53) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL26035299 | 0.72 | TK2 (0.53) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL24205273 | 0.72 | CYP2C9 (0.44) | POLBAPEX1HTTTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | POLB 1376/4885APEX1 133/4885HTT 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.